

**PATENTS**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Henkin, et al.

SERIAL No.: (not yet assigned)

FILED: January 23, 2004

FOR: PEPTIDE ANTIANGIOGENIC  
DRUGS

GROUP ART NO.: (not yet assigned)

EXAMINER: (not yet assigned)

CASE NO.: 6356.US.C1


Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Express Mail Label No.: EV321156871US

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service under 37 C.F.R. 1.10 addressed to:

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on:

Date of Deposit: January 23, 2004

 1/23/04  
Tanya Parent Date

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form.


Applicants submit herewith the Form PTO-1449 listing the references cited in this Information Disclosure Statement. The listed references are available for the Examiner to review in the file of the U.S. Serial No. 09/447,226. If the Examiner needs further copies of any cited references, the Examiner is respectfully requested to contact the undersigned attorney.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,  
Henkin, et al.

ABBOTT LABORATORIES  
Customer Number 23492  
Telephone: (847) 937-8272  
Facsimile: (847) 938-2623

  
Johanna M. Corbin  
Registration No. 51,582  
Attorney for Applicants

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6356.US.C1

SERIAL NO.

Not yet assigned

APPLICANT(S)

J. Henkin, et al.

FILING DATE

January 23, 2004

GROUP

Not yet assigned

## U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	5,155,038	10/13/92	Eyal et al.			
	A2	5,190,918	03/02/93	Duetch, et al.			
	A3	5,190,920	03/02/93	Eyal et al.			
	A4	5,192,744	03/09/93	Bouck, et al.			
	A5	5,200,937	04/06/93	Deutch, et al.			
	A6	5,367,059	11/22/94	Tuszynski et al.			
	A7	5,426,100	06/20/95	Deutch, et al.			
	A8	5,491,130	02/13/96	Roberts et al.			
	A9	5,506,208	04/09/96	Eyal et al.			
	A10	5,648,461	07/15/97	Eyal et al.			
	A11	5,654,277	08/05/97	Eyal et al.			
	A12	5,770,563	06/23/98	Roberts et al.			
	A13	5,840,692	11/24/98	Deutch et al.			
	A14	5,849,701	12/15/98	Roberts et al.			
	A15	6,051,549	04/18/00	Roberts et al.			
	A16	6,239,110	05/29/01	Eyal et al.			
	A17	6,339,062	01/15/02	Williams et al.			
	A18	6,380,161	04/30/02	Williams et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
							YES	NO
	B1	0443404A	28.08.91	EPO				
	B2	9316716A	02.09.93	WO				
	B3	96/11214	18.04.96	WO				
	B4	9741824A	13.11.97	WO				
	B5	9841542A	24.09.98	WO				

**OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)**

C1	Belo, Inflammation 25(2):91-96 (2001)
C2	Donoviel, J. Biological Chemistry, 263:18590-18593 (1988)
C3	Gasparini, et al., Journal of Clinical Oncology 13(3):765-782
C4	Haverstick, et al., Biochemistry, 23:5597-5603
C5	Hennesy, et al., J. Cell Biology, 108:729-736 (1989)
C6	Lawler and Hynes, J. Cell Biology, 103:1635-1648 (1986)
C7	Majack and Bornstein, Cell Membranes Methods-Reviews, 3:55-77
C8	Mundhenke, Clinical Cancer Research 7(11):3366-3374 (2001)
C9	Nicosia, American Journal of Pathology 138(4):829-833 (1991)
C10	Pignatelli, Human Pathology 23(10):1159-1156 (1992)
C11	Reiher, Int. J. Cancer 98:682 (2002)
C12	Santoro and Frazier, Methods of Enzymology, 144:438-446 (1987)

**EXAMINER****DATE CONSIDERED**

**EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

(Form PTO 1449)

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6356.US.C1

SERIAL NO.

Not yet assigned

APPLICANT(S)

J. Henkin, et al.

FILING DATE

January 23, 2004

GROUP

Not yet assigned

## U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	5,155,038	10/13/92	Eyal et al.			
	A2	5,190,918	03/02/93	Duetch, et al.			
	A3	5,190,920	03/02/93	Eyal et al.			
	A4	5,192,744	03/09/93	Bouck, et al.			
	A5	5,200,937	04/06/93	Deutch, et al.			
	A6	5,367,059	11/22/94	Tuszynski et al.			
	A7	5,426,100	06/20/95	Deutch, et al.			
	A8	5,491,130	02/13/96	Roberts et al.			
	A9	5,506,208	04/09/96	Eyal et al.			
	A10	5,648,461	07/15/97	Eyal et al.			
	A11	5,654,277	08/05/97	Eyal et al.			
	A12	5,770,563	06/23/98	Roberts et al.			
	A13	5,840,692	11/24/98	Deutch et al.			
	A14	5,849,701	12/15/98	Roberts et al.			
	A15	6,051,549	04/18/00	Roberts et al.			
	A16	6,239,110	05/29/01	Eyal et al.			
	A17	6,339,062	01/15/02	Williams et al.			
	A18	6,380,161	04/30/02	Williams et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
							YES	NO
	B1	0443404A	28.08.91	EPO				
	B2	9316716A	02.09.93	WO				
	B3	96/11214	18.04.96	WO				
	B4	9741824A	13.11.97	WO				
	B5	9841542A	24.09.98	WO				

**OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)**

C1	Belo, Inflammation 25(2):91-96 (2001)
C2	Donoviel, J. Biological Chemistry, 263:18590-18593 (1988)
C3	Gasparini, et al., Journal of Clinical Oncology 13(3):765-782
C4	Haverstick, et al., Biochemistry, 23:5597-5603
C5	Hennessey, et al., J. Cell Biology, 108:729-736 (1989)
C6	Lawler and Hynes, J. Cell Biology, 103:1635-1648 (1986)
C7	Majack and Bornstein, Cell Membranes Methods-Reviews, 3:55-77
C8	Mundhenke, Clinical Cancer Research 7(11):3366-3374 (2001)
C9	Nicosia, American Journal of Pathology 138(4):829-833 (1991)
C10	Pignatelli, Human Pathology 23(10):1159-1156 (1992)
C11	Reiher, Int. J. Cancer 98:682 (2002)
C12	Santoro and Frazier, Methods of Enzymology, 144:438-446 (1987)

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

(Form PTO 1449)